Navigation Links
Trius Announces Issuance of Key U.S. Patent for Torezolid Phosphate
Date:10/25/2010

SAN DIEGO, Oct. 25 /PRNewswire/ -- Trius Therapeutics, Inc. (Nasdaq: TSRX) announced today the issuance of Patent Number 7,816,379, entitled "Oxazolidinone Derivatives," by the United States Patent and Trademark Office (USPTO). The new patent, which is exclusively licensed to Trius, protects the Company's lead investigational drug, torezolid phosphate (TR-701), currently in Phase 3 clinical testing in patients with acute bacterial skin and skin structure infections (ABSSSI). The patent can be viewed on the USPTO's website at www.uspto.gov. Trius also has licensed patents in Australia, New Zealand, and India, and a patent application in Russia where a notice of allowance was recently issued.  Counterpart applications are also pending in additional territories.

"The issuance of this patent adds to our robust intellectual property portfolio for torezolid phosphate, the only second-generation oxazolidinone in Phase 3 development," said Jeffrey Stein, Ph.D., President and Chief Executive Officer of Trius.  "These issued claims are expected to provide patent exclusivity for torezolid phosphate through late 2026."

Trius acquired worldwide rights outside of North and South Korea to a family of patent applications that provide patent coverage for composition of matter and methods of making and using torezolid phosphate through an exclusive license from Dong-A Pharmaceuticals in 2007.  In addition to the U.S. patent and the four allowed or issued foreign patents mentioned above, Trius has filed patent applications directed to other aspects of torezolid phosphate discovered by Trius' scientists. Patents which may issue from these additional applications could provide patent exclusivity for torezolid phosphate through 2030.

About Trius Therapeutics

Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious, life-threatening infections. The company's lead investigational drug, torezolid phosphate, is an IV and orally administered second generation oxazolidinone in Phase 3 clinical development for the treatment of acute bacterial skin and skin structure infections (ABSSSI), the first such trial to be initiated under a Special Protocol Assessment (SPA). In addition to the company's torezolid phosphate clinical program, it is currently conducting two preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by gram-negative bacteria. For more information, visit www.triusrx.com.

Forward-Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the potential benefits and protections afforded to Trius through current or potential patents and the potential duration of those benefits. Risks that contribute to the uncertain nature of the forward-looking statements include: Trius' ability to obtain additional financing; the success and timing of Trius' preclinical studies and clinical trials; regulatory developments in the United States and foreign countries; the performance of third-party manufacturers; changes in Trius' plans to develop and commercialize its product candidates; Trius' ability to obtain and maintain intellectual property protection for its product candidates; Trius' ability to freely commercialize its product candidates; and the loss of key scientific or management personnel. These and other risks and uncertainties are described more fully in Trius' most recently filed SEC documents, including its Registration Statement on Form S-1 that was originally filed with the United States Securities and Exchange Commission on November 6, 2009, and the amendments thereto, and Trius' Form 10-Q for the quarter ended June 30, 2010, including those factors discussed under the caption "Risk Factors" in such filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trius undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.


'/>"/>
SOURCE Trius Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Trius Reports New Findings on Mechanisms of Antibiotic Resistance in MRSA
2. Trius to Present at the Stifel Nicolaus Healthcare Conference
3. Trius Therapeutics Obtains Special Protocol Assessment With FDA for Phase 3 Study of Torezolid Phosphate
4. Trius Therapeutics Files Registration Statement for Proposed Initial Public Offering
5. Trius Torezolid Antibiotic for the Treatment of Severe Skin Infections Featured at ICAAC Meeting
6. Trius Announces Positive Results From Phase 2 Clinical Trial of Torezolid in Patients With Complicated Skin and Skin Structure Infections
7. Trius Therapeutics Announces Presentations Featuring Torezolid Antibiotic at the 19th European Congress of Clinical Microbiology and Infectious Diseases
8. Trius Completes Enrollment in Phase 2 Clinical Trial Evaluating Torezolid (TR-701) in Patients With Complicated Skin and Skin Structure Infections
9. Trius Antibiotics to be Highlighted in 18 Presentations at ICAAC/IDSA
10. Trius Doses First Patient in Antibacterial Phase 2 Trial
11. PacificGMP Completes GMP Product Fill for Trius Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2017)... 20, 2017  Cogentix Medical, Inc. (NASDAQ: CGNT), ... the Urology, Uro/Gyn and Gynecology markets with innovative ... has joined the Company as Senior Vice President, ... position, Mr. Keswani will report directly to ... "Our organization is delighted that Ash has joined ...
(Date:4/20/2017)... 2017 Research and Markets has announced the ... by Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics ... ... will rise from USD 20 Billion in 2015 to around USD ... Technologies - Innovation Driven by Rapidly Expanding Injectables Market and Increasing ...
(Date:4/20/2017)... Eyevensys, a private biotechnology company ... expression technology that enables the safe, local, sustained production ... wide range of ophthalmic diseases, announces it has received ... Agency (MHRA) to advance its technology into clinical development. ... The EyeCET ...
Breaking Medicine Technology:
(Date:4/25/2017)... ... April 25, 2017 , ... ProRehab Physical Therapy (PRPT) ... preferred physical therapy provider for Derby City CrossFit, effective immediately. , In addition ... quickly and effectively as possible, ProRehab’s sports physical therapists will work with athletes ...
(Date:4/25/2017)... ... April 25, 2017 , ... A ... student test score performance for the 2015-16 school year across Wisconsin’s public schools, ... Though it highlights important patterns in student test score performance, the report’s limited ...
(Date:4/25/2017)... ... April 25, 2017 , ... As pharmaceutical ... partners to help with process innovation in drug formulation and manufacturing. CoreRx ... with state-of-the-art analytical equipment in support of their development and manufacturing goals. ...
(Date:4/25/2017)... ... ... MD is committed to providing the highest quality of spine care to all his patients. ... all my patients to alleviate possible future issues. I am pleased to have you as ... my trained staff will assist you in any way possible.” , Dr. Saad Chaudhary is ...
(Date:4/25/2017)... ... April 25, 2017 , ... ... healthcare products, is introducing Flexadin UCII, part of the EQUISTRO line, at this ... joint health in horses at the immunologic level. , The scientifically-developed Flexadin UCII ...
Breaking Medicine News(10 mins):